EP1379132A4 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number: EP1379132A4
Authority: EP; European Patent Office
Prior art keywords: secreted proteins; human secreted; human; proteins; secreted
Prior art date: 2001-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02760994A

Other languages

German (de)

French (fr)

Other versions

EP1379132A2 (en

Inventor

Craig A Rosen

Steven M Ruben

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2002-03-19

Publication date

2009-07-01

2002-03-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2004-01-14 Publication of EP1379132A2 publication Critical patent/EP1379132A2/en

2009-07-01 Publication of EP1379132A4 publication Critical patent/EP1379132A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP02760994A 2001-03-21 2002-03-19 Human secreted proteins Withdrawn EP1379132A4 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US27734001P	2001-03-21	2001-03-21
US277340P		2001-03-21
US30617101P	2001-07-19	2001-07-19
US306171P		2001-07-19
US33128701P	2001-11-13	2001-11-13
US331287P		2001-11-13
PCT/US2002/008278 WO2002102994A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Publications (2)

Publication Number	Publication Date
EP1379132A2 EP1379132A2 (en)	2004-01-14
EP1379132A4 true EP1379132A4 (en)	2009-07-01

Family

ID=27402891

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
EP02799146A Withdrawn EP1390390A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications Before (6)

Application Number	Title	Priority Date	Filing Date
EP02799146A Withdrawn EP1390390A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en)	2001-03-21	2002-03-19	Human secreted proteins

Country Status (4)

Country	Link
EP (7)	EP1390390A4 (en)
AU (6)	AU2002363296A1 (en)
CA (7)	CA2441397A1 (en)
WO (7)	WO2002090526A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196164B2 (en)	1997-07-08	2007-03-27	Human Genome Sciences, Inc.	Secreted protein HHTLF25
CA2295474A1 (en)	1997-07-08	1999-01-21	Human Genome Sciences, Inc.	123 human secreted proteins
ES2629442T3 (en)	1998-06-01	2017-08-09	Agensys, Inc.	New transmembrane serpentine antigens expressed in human cancers and uses thereof
US20040141975A1 (en)	1998-06-01	2004-07-22	Raitano Arthur B.	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20060052321A1 (en)	2002-04-05	2006-03-09	Raitano Arthur B	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en)	2000-12-06	2003-08-07	Hubert Rene S.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en)	1999-06-01	2004-12-21	Agensys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
JP5550799B2 (en)	1999-01-15	2014-07-16	バイオジェン・アイデック・エムエイ・インコーポレイテッド	TWEAK antagonists and TWEAK receptor antagonists and their use to treat immunological disorders
US7291719B2 (en)	2000-07-25	2007-11-06	Genentech, Inc.	PRO4332 antibodies
EP1666490A3 (en) *	2000-07-25	2006-11-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1364021A2 (en)	2000-10-31	2003-11-26	Diadexus, Inc.	Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) *	2000-11-30	2002-08-15	Y. Tom Tang	Novel nucleic acids and polypeptides
AU2002318112B2 (en) *	2001-04-10	2007-12-06	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030100497A1 (en)	2001-06-20	2003-05-29	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en)	2001-09-06	2009-02-24	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003022995A2 (en)	2001-09-06	2003-03-20	Agensys, Inc.	Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7097990B2 (en)	2001-10-12	2006-08-29	Astellas Pharma Inc.	Method of screening cell death inhibitor
CN106421778A (en)	2002-04-09	2017-02-22	比奥根Ma公司	Methods for treating tweak-related conditions
AU2003900747A0 (en) *	2003-02-18	2003-03-06	Garvan Institute Of Medical Research	Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP2336360A1 (en)	2003-09-23	2011-06-22	University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
ES2379764T3 (en) *	2003-10-14	2012-05-03	Baxter International Inc.	VKORC1 recycling polypeptide of vitamin K-epoxide, a therapeutic target of curamine and its derivatives
WO2005076003A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en)	2004-02-20	2005-08-25	Yixin Wang	Breast cancer prognostics
CA2563735C (en)	2004-04-22	2020-07-14	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to steap-1 proteins
NZ553581A (en) *	2004-09-01	2011-04-29	Dynavax Tech Corp	Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
WO2006026807A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Agents for treatment or prevention of an allergic disorder
CA2579705A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Method of diagnosing and/or predicting the development of an allergic disorder
EP1859277A4 (en)	2005-02-17	2010-03-17	Biogen Idec Inc	Treating neurological disorders
US9617523B2 (en)	2005-02-28	2017-04-11	Baxalta GmbH	Nucleic acids encoding vitamin K expoxide reductase subunit 1 and vitamin K dependent protein expression and methods of using same
US20090325226A1 (en)	2005-03-15	2009-12-31	Stafford Darrel W	Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
JP5339901B2 (en)	2005-05-10	2013-11-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Treatment and evaluation of inflammatory injury
WO2006138219A2 (en) *	2005-06-13	2006-12-28	Biogen Idec Ma Inc.	Methods of diagnosis / prognosis of inflammatory conditions
US20090054307A1 (en) *	2005-09-01	2009-02-26	Howard Florey Institute Of Experimental Physiology And Medicine	Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) *	2005-10-21	2005-11-30	Ares Trading Sa	Integral membrane protein
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
EP2061814B1 (en)	2006-10-27	2012-06-06	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
CN101636179B (en)	2006-11-07	2012-10-10	默沙东公司	Antagonists of pcsk9
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
CA2680832A1 (en)	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en)	2007-08-23	2023-03-28	Amgen Inc	Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en)	2007-10-26	2017-03-01	Dynavax Technologies Corporation	Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) *	2007-11-30	2013-06-19	西门子医疗保健诊断公司	Adiponectin receptor fragments and methods of use
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
US8802827B2 (en)	2009-10-30	2014-08-12	Merck Sharp & Dohme Corp.	AX1 PCSK9 antagonists
AU2010313324A1 (en)	2009-10-30	2012-04-12	Merck Sharp & Dohme Corp.	AX213 and AX132 PCSK9 antagonists and variants
EA201291357A1 (en)	2010-06-16	2013-11-29	Дайнэвокс Текнолоджиз Корпорейшн	TREATMENT METHODS USING TLR7 AND / OR TLR9 INHIBITORS
CA2810928A1 (en)	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
EP2655607A4 (en)	2010-12-21	2014-05-14	Univ North Carolina	Methods and compositions for producing active vitamin k-dependent proteins
WO2013096680A1 (en)	2011-12-22	2013-06-27	Alios Biopharma, Inc.	Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en)	2012-03-21	2013-09-26	Vertex Pharmaceuticals Incorporated	Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en)	2012-03-22	2016-01-29	Alios Biopharma Inc	Pharmaceutical combinations comprising a thionucleotide analog
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9682218B2 (en)	2013-12-23	2017-06-20	Carefusion 2200, Inc.	Pleurodesis device and method
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018119354A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Gene editing of pcsk9
JP7247101B2 (en)	2017-04-03	2023-03-28	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Antibody that binds to STEAP-1
CN110709174A (en)	2017-06-22	2020-01-17	宝洁公司	Film comprising a water-soluble layer and a vapor-deposited organic coating
EP3642383B1 (en) *	2017-06-22	2022-12-21	The Procter & Gamble Company	Films including a water-soluble layer and a vapor-deposited inorganic coating
CN116096429A (en)	2020-04-09	2023-05-09	维乎医疗有限公司	Base editing of PCSK9 and methods of use thereof for treating diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100236393B1 (en) *	1996-02-02	1999-12-15	나까니시 히로유끼	A pharmaceutical preparation containing a human growth hormone
US5858716A (en) *	1997-05-30	1999-01-12	Smithkline Beecham Corporation	H2CAA71 polynucleotides

2002
- 2002-03-19 CA CA002441397A patent/CA2441397A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/en not_active Application Discontinuation
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/en not_active Application Discontinuation
- 2002-03-19 CA CA002441755A patent/CA2441755A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/en not_active Application Discontinuation
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 EP EP02799146A patent/EP1390390A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/en not_active Application Discontinuation
- 2002-03-19 CA CA002441416A patent/CA2441416A1/en not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/en not_active Withdrawn
- 2002-03-19 EP EP02723499A patent/EP1379264A4/en not_active Withdrawn
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/en not_active Application Discontinuation
- 2002-03-19 EP EP02759068A patent/EP1404702A4/en not_active Withdrawn
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 EP EP02780789A patent/EP1423134A2/en not_active Withdrawn
- 2002-03-19 CA CA002441832A patent/CA2441832A1/en not_active Abandoned
- 2002-03-19 EP EP02782476A patent/EP1414845A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/en not_active Application Discontinuation
- 2002-03-19 EP EP02760994A patent/EP1379132A4/en not_active Withdrawn
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 CA CA002441417A patent/CA2441417A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/en not_active Application Discontinuation
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 CA CA002441840A patent/CA2441840A1/en not_active Abandoned
- 2002-03-19 CA CA002441702A patent/CA2441702A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins

Also Published As

Publication number	Publication date
WO2002102994A3 (en)	2003-07-24
CA2441397A1 (en)	2002-10-03
AU2002354719A1 (en)	2003-01-21
AU2002332391A1 (en)	2003-01-02
CA2441702A1 (en)	2002-12-27
WO2003038063A2 (en)	2003-05-08
CA2441416A1 (en)	2003-01-16
WO2002095010A2 (en)	2002-11-28
EP1414845A4 (en)	2009-07-08
WO2003004622A2 (en)	2003-01-16
AU2002363296A1 (en)	2003-05-12
WO2002095010A3 (en)	2004-02-12
WO2002076488A1 (en)	2002-10-03
EP1379264A4 (en)	2009-07-08
EP1379264A1 (en)	2004-01-14
CA2441755A1 (en)	2003-05-08
WO2002102993A3 (en)	2004-03-25
EP1390390A2 (en)	2004-02-25
EP1404702A2 (en)	2004-04-07
WO2003004622A3 (en)	2004-02-19
AU2002320013A1 (en)	2002-11-18
WO2002102994A2 (en)	2002-12-27
AU2002326293A1 (en)	2003-01-02
WO2002102993A2 (en)	2002-12-27
AU2002324424A1 (en)	2002-12-03
EP1423134A2 (en)	2004-06-02
CA2441417A1 (en)	2002-11-14
WO2002090526A3 (en)	2003-10-30
EP1381622A2 (en)	2004-01-21
CA2441832A1 (en)	2002-12-27
CA2441840A1 (en)	2002-11-28
EP1390390A4 (en)	2009-07-08
EP1379132A2 (en)	2004-01-14
EP1404702A4 (en)	2009-07-08
WO2002090526A2 (en)	2002-11-14
WO2003038063A3 (en)	2003-12-11
EP1414845A2 (en)	2004-05-06

Publication	Publication Date	Title
EP1379264A4 (en)	2009-07-08	Human secreted proteins
EP1383888A4 (en)	2005-03-30	Human secreted proteins
EP1251863A4 (en)	2005-03-02	22 human secreted proteins
AU2002361452A8 (en)	2003-07-09	Secreted proteins
GB0218205D0 (en)	2002-09-11	Human ZZAP1 protein
IL162598A0 (en)	2005-11-20	Secreted protein
AU2002232596A1 (en)	2002-06-24	Secreted human proteins
AU2002354803A8 (en)	2008-03-13	Secreted proteins
EP1368468A4 (en)	2005-02-16	83 human secreted proteins
AU2003301843A8 (en)	2004-06-07	157 human secreted proteins
EP1385977A4 (en)	2005-02-16	Secreted proteins
AU2001294719A1 (en)	2002-04-08	Secreted human proteins
EP1370651A4 (en)	2005-04-06	70 human secreted proteins
EP1417224A4 (en)	2005-08-10	Secreted proteins
AU2002365153A1 (en)	2003-06-30	41 human secreted proteins
EP1404807A4 (en)	2005-03-23	20 human secreted proteins
AU2002246998A1 (en)	2002-07-30	50 human secreted proteins
AU2002348034A8 (en)	2009-07-30	16 human secreted proteins
AU2002254275A1 (en)	2002-10-08	Human secreted proteins
AU2002303843A8 (en)	2007-09-20	Secreted proteins
AU2003211136A8 (en)	2003-10-08	6 human secreted proteins
AU2002247189A1 (en)	2002-09-12	70 human secreted proteins
AU2002253985A1 (en)	2002-09-12	83 human secreted proteins
AU2002332483A1 (en)	2003-02-24	13 human secreted proteins
EP1443818A4 (en)	2006-03-08	Novel secreted proteins and their uses

Legal Events

Date	Code	Title	Description
2003-11-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-01-14	17P	Request for examination filed	Effective date: 20031021
2004-01-14	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2004-01-14	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2009-07-01	A4	Supplementary search report drawn up and despatched	Effective date: 20090603
2009-07-01	RIC1	Information provided on ipc code assigned before grant	Ipc: C07H 21/02 20060101ALI20090527BHEP Ipc: C07K 1/00 20060101AFI20090527BHEP
2010-02-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-03-10	18D	Application deemed to be withdrawn	Effective date: 20090903